Full article: Acute kidney injury in patients receiving high-dose etoposide phosphate as
conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be …

… , either by replacing carmustine in the … acute kidney injury (rAKI) in 51 out of 122 patients
of the cohort undergoing conditioning including intensified bendamustine before autologous …

… , including a high rate of acute renal failure and higher rates of … since patients with chronic
kidney disease or significant hepatic … , carmustine, and etoposide followed by autologous bone …

… has limited its use bringing our institution to replace carmustine … However, acute kidney
injury was frequent (27.9%) and was … of rituximab in maintenance after autologous HSCT has …

… The combination of carmustine, etoposide, cytarabine, and … Briefly, acute kidney failure
(ARF) was defined according to … the normal value at 10 (6 to 21) days after graft infusion. Two …

… , which occurs in 10% to 70% of patients following treatment … The incidence of acute kidney
injury (AKI) in autologous stem … stage 5 disease, four of whom required maintenance dialysis …

… begun implementing bendamustine, etoposide, cytarabine and … Events v4.0) following
bendamustine administration, with … use could contribute to acute kidney injury. Cohort studies …

… instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) …
was acute renal failure, which developed in four patients (6.7%) shortly after bendamustine …

… administered in the setting of acute kidney disease or CKD (… etoposide and bleomycin, no
significant change in kidney … of the total carmustine dose is excreted in the urine within 3 days. …

… consisting of BCNU (carmustine), etoposide, cytarabine, and … After G-CSF administration,
autologous stem cells were … acute kidney injury of any grade, and transient hemodialysis was …